Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.
Masaomi NangakuWilliam G HerringtonShinya GotoShoichi MaruyamaNaoki KashiharaKohjiro UekiJun WadaHirotaka WatadaEitaro NakashimaRyonfa LeeDan MasseyKaitlin J MayneAiko TomitaRichard HaynesSibylle J HauskeTakashi KadowakiPublished in: Clinical and experimental nephrology (2024)
Empagliflozin safely reduced the risk of "kidney disease progression or cardiovascular death" in patients with CKD, with consistent effects in participants from Japan.
Keyphrases